With cardiovascular disease remaining a major cause of morbidity and mortality despite recent therapeutic advances, the molecular basis of heart failure continues to be an active field of investigation. In particular, the renin-angiotensin system, which plays a major role in blood pressure control and cardiac hypertrophy, has been the subject of countless studies. The renin-angiotensin system comprises a complex set of proteolytic processing steps and interconnected signaling pathways, acting both systemically and locally and involving multiple angiotensin peptides and receptors. Of these, the most extensively studied are angiotensin II (AngII), considered to be the major effector molecule of the renin-angiotensin system, and one of its receptors, the AngII type 1 receptor (AT1R).

Two decades ago, AngII treatment and mechanical stretch were shown to have similar effects on cardiomyocyte signal transduction pathways and gene expression, resulting in hypertrophic growth that was found to be mediated primarily by the AT1R. Later studies showed that mechanical stress can activate the AT1R even in the absence of AngII, with ligand binding and mechanical stress causing distinct conformational changes in the receptor. The AT1R is a G protein–coupled receptor that mediates the hypertrophic effects of AngII by triggering downstream signaling through coupled heterotrimeric G proteins. Binding of AngII also causes recruitment of β-arrestin, which, in turn, leads to receptor desensitization and internalization. Ligand-independent or β-arrestin–biased activation of the receptor, on the other hand, is independent of G protein signaling and induces distinct conformational changes in the receptor and in β-arrestin that trigger an alternative, cardioprotective downstream signaling pathway.

What happens to the AT1R after internalization? In the current model, sorting of endosomal AT1R leads to 1 of 3 fates: interaction with other molecules to participate in intracellular signaling, resensitization and recycling of the receptor back to the plasma membrane, or lysosomal degradation. In this issue of Circulation, Pironti et al provide evidence of a fourth possibility with potentially far-reaching consequences. Cardiac cells are capable of secreting multiple autocrine/paracrine factors, including AngII, thereby exerting effects beyond the individual cell. In addition, stress may promote release of exosomes, extracellular membrane vesicles capable of carrying a variety of cargoes, including proteins and nucleic acids, for transfer to other cells in the local environment or farther off via the systemic circulation. Exosomes, which are secreted by a variety of cell types and exist at high concentrations in the blood, originate from endosomal formation of intraluminal vesicles within multivesicular bodies, and they are released from the cell by fusion of the multivesicular bodies with the cell membrane. In this study, using rigorous methods of purification and quantification, the authors show that exosome secretion increases significantly after either osmotic stretch or AngII treatment of HEK293T cells (with or without stable expression of AT1R) in vitro or 7 days of cardiac pressure overload in wild-type (WT) mice in vivo. Furthermore, some of the exosomes were found to contain AT1R, with the receptor density in the cell media and serum increasing substantially after stimulation with osmotic stretch or AngII in vitro or pressure overload in vivo. Transfer of these exosomes to WT HEK293T cells (which do not express AT1R) or AT1R knockout mice caused the recipients to become responsive to AngII treatment, demonstrating that the exosomal AT1Rs remain functional. Thus, it appears that internalization not only is not necessarily the end of the line for AT1Rs but may actually be part of a process that allows cardiac cells to extend the reach of their signaling to more distant tissues (Figure).

Packaging of AT1R into exosomes was found to be dependent on the presence of β-arrestin, in particular β-arrestin-2. It is not surprising given that β-arrestin is known to play an essential role in AT1R internalization by disrupting receptor/G protein interaction and recruiting components of the endocytic machinery. One question that has not yet been addressed, however, is precisely what role, if any, β-arrestin-2 plays in directing AT1R to exosomes rather than one of the alternative possible fates. Although global β-arrestin-2 knock-out prevented AT1R packaging, exosomal release was unaffected. Nor does the increase in exosome release appear to be dependent on the AT1R itself because WT HEK293T cells also released an increased number of exosomes in response to osmotic stretch, although it might be helpful to confirm this observation in vivo by examining exosomal release in response to pressure overload in AT1R knockout mice. Both AngII and mechanical stretch were used to stimulate exosome release, but these 2 stimuli have previously been shown to induce different β-arrestin conformations and to trigger different downstream signaling pathways, with the latter being independent of ligand binding, at least in the short term.
the long term, however, some of the effects of stretch and pressure overload are also mediated by AngII/AT1R signaling. Hypotonic stress–induced c-fos upregulation in cardiomyocytes was unaffected by treatment with an AT1R antagonist, but mechanical stretch and pressure overload have been shown to induce secretion of AngII. What, then, is the common mechanism by which the different types of stimulus increase AT1R-containing exosome release, and how is the AT1R, rather than other receptors, specifically targeted for exocytosis? If AngII ligand binding is required, testing the effects of treatment with AT1R blockers or angiotensinogen knockout on AT1R packaging could be informative. Mechanical stretch induces internalization of the AT1R, which forms a more stable class B–type interaction with β-arrestin, but not of the β1-adrenergic receptor, which forms a less stable class A-type interaction, and this may perhaps account for the specific inclusion of AT1Rs. However, even under stimulated conditions, the AT1R density was <10 receptors per 100 exosomes, suggesting that something else may be packaged into the exosomes under these conditions as well. If so, what else are the exosomes carrying and why?

As mentioned, global knockout of β-arrestin-2 prevented transfer of AT1Rs to the exosomes during pressure overload in vivo. Similarly, cardiomyocyte-specific β-arrestin-2 knockout markedly reduced serum AT1R levels of tamoxifen-treated β-arrestin−/−MHC−/−Cre/−Mice mice after 7 days of pressure overload. From this observation, the authors concluded that cardiomyocytes are the major source of AT1R-containing exosomes during pressure overload in vivo. Cardiomyocytes have been shown to secrete a number of soluble factors that modulate the functions of surrounding cells, and it was recently demonstrated that regulation of Mediator complex subunit 13 signaling in cardiomyocytes controls lipid use and oxygen consumption in white adipose tissue and the liver, presumably through circulating factors released by the heart. Nevertheless, exocytosis of functional receptors would represent a significant extension of the mechanistic network by which cardiomyocytes can exert control over other cells and tissues at a distance. However, a possibility exists that this conclusion may prove to be premature. No direct evidence is presented to confirm that cardiomyocytes are the source of the exosomes, nor are there any data on the cardiac function of the cardiac-specific β-arrestin-2 knockout mice. It is therefore possible that the AT1R-containing exosomes are released from other cardiac cells as a secondary effect of changes in cardiac function after pressure overload. AT1R expression is relatively low in cardiomyocytes, whereas it is substantially higher in cardiac fibroblasts. Furthermore, cardiac fibroblasts have been shown to secrete cytokines and exosomes that induce hypertrophy in cardiomyocytes, raising the question of whether they could also be involved in the observed AT1R-containing exosome release during pressure overload. The authors do not address a secondary effect of the cardiac-specific β-arrestin-2 knockout that makes interpretation of the data difficult, namely that, although cardiomyocyte levels of β-arrestin-2 were ~80% lower in the cardiac-specific β-arrestin-2 knockout mice than in WT mice, there was an ~4-fold increase in β-arrestin-2 levels in cardiac fibroblasts (see Figure IIIID in the online-only Data Supplement for the Pironti et al article). It is unclear how this might affect circulating AT1R levels. However, it may be that the exosomes are actually derived from cardiac fibroblasts rather than cardiomyocytes and that it is the excess β-arrestin-2 in the fibroblasts of the knockout mice that is responsible for the decrease in

Figure. Schematic representation of the formation of angiotensin II (AngII) type 1 receptor (AT1R)–containing exosomes. Stimulation by AngII or mechanical stress activates the AT1R, triggering recruitment of β-arrestin-2. β-Arrestin-2, in turn, recruits components of the endocytic machinery, leading to internalization of the AT1R. Endosomal AT1R is packaged via a currently unknown mechanism into intraluminal vesicles within multivesicular bodies, which are released as exosomes on fusion of the multivesicular bodies with the cell membrane. Circulating AT1R-exosomes target the cardiomyocytes and mesenteric vessels in the heart and skeletal muscle.
circulating AT1R, possibly by allowing AT1R internalization but somehow preventing its exocytosis, rather than the decrease in cardiomyocyte β-arrestin-2. Further investigation of AT1R internalization and exosome tracking in the different cell types is required to address this issue.

This study clearly represents a significant advance in understanding how the local cardiac renin-angiotensin system can exert its effects systemically. Although AngII is secreted into the circulation, the responsiveness of target cells was, until now, thought to be dependent on their intrinsic AT1R densities. It now appears that cardiac cells take part in determining not just how much of the effector molecule is released but also how capable its targets are of responding to it. What remains unclear at this point is the functional significance of this mechanism. Pironti et al. used AT1R knockout mice to demonstrate that the AT1Rs in exosomes remain functional, causing increases in blood pressure and phosphorylation of extracellular signal-regulated kinase in response to AngII treatment in vivo. However, they did not inject WT mice, so it is unknown whether the introduction of exogenous AT1R-containing exosomes would have a significant additive effect over that of the endogenous receptors. Examination of receptordensity in the tissues of WT and AT1R knockout mice revealed that the exosomes specifically target the heart and skeletal muscle but not the kidneys or lungs and that, within the heart, they traffic to cardiomyocytes and the endothelial and smooth muscle cells of mesenteric vessels but not to cardiac fibroblasts. Exosomal markers reflect their parent cells, and it is thought that uptake depends on binding of targeting peptides to receptors on recipient cells. Indeed, increasing targeting peptide stability was recently shown to significantly increase exosomal uptake. Furthermore, there is evidence that the endocytic pathway by which exosomes are internalized varies and may be specific to the cell type. Thus, how the specific targeting of AT1R-exosomes is achieved and how they are taken up by the target cells remain to be elucidated. Likewise, the purpose of the receptor transfer has yet to be determined. The authors speculate that the release of AT1Rs may represent an attempt to offset receptor downregulation in the presence of increased AngII levels and that this may aggravate cardiac dysfunction and remodeling during pressure overload. If AT1R-containing exosome release is involved in the progression of heart failure, selectively inhibiting this process could represent a novel therapeutic modality. G protein–coupled receptor kinases (GRKs) are required for G protein–coupled receptor internalization, and paroxetine, which specifically inhibits GRK2, was recently demonstrated to be of greater benefit in protecting the heart after myocardial infarction in mice than currently used β-blocker therapy. However, AT1R/β-arrestin-2–dependent extracellular signal-regulated kinase activation in response to mechanical stretch was shown to require GRK5 and GRK6 rather than GRK2. GRK5-specific small-molecule inhibitors are currently under investigation and may prove to be of use in targeting pressure overload–induced AT1R exocytosis. On the other hand, knockout of either AT1R or β-arrestin-2 has been shown to decrease Akt phosphorylation and to increase apoptosis in the mouse heart after mechanical stress, indicating that activation of the AT1R by mechanical stress triggers prosurvival signaling. This raises the possibility that the AT1R-exosome release, which is also triggered by mechanical stress in a β-arrestin-2–dependent manner, may also represent a protective mechanism. A recent study found that plasma exosomes collected from normal rats or humans were highly protective against cardiac ischemia/reperfusion injury in rats, supporting the idea that, at least under some conditions, exosomes may have a cardioprotective role. If so, it remains to be determined whether further upregulation of the process would be of therapeutic value for combating the progression of heart failure.

Acknowledgments
We sincerely thank Dr Susmita Sahoo for her helpful suggestions.

Sources of Funding
This work was supported in part by US Public Health Service grants HL102738, HL67724, HL91469, AG23039, and HL112330. This work was also supported by the Fondation Leducq Transatlantic Networks of Excellence.

Disclosures
None.

References


**Key Words:** Editorials ◼ exosomes ◼ receptors, angiotensin ◼ stretch
Inside-Out Signaling: Moving the AT1 Receptor in to Get the Message Out
Daniela Zablocki and Junichi Sadoshima

_Circulation_. 2015;131:2097-2100; originally published online May 20, 2015; doi: 10.1161/CIRCULATIONAHA.115.016978

_Circulation_ is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2015 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circ.ahajournals.org/content/131/24/2097

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in _Circulation_ can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to _Circulation_ is online at:
http://circ.ahajournals.org//subscriptions/